---
title: "Uncovering Potential: NRX Pharmaceuticals's Earnings Preview"
description: "NRX Pharmaceuticals (NRXP) is set to release its quarterly earnings report on May 15, 2025, with analysts predicting an earnings per share (EPS) of $-0.40. Investors are hopeful for positive guidance "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/240217076.md"
published_at: "2025-05-14T17:09:59.000Z"
---

# Uncovering Potential: NRX Pharmaceuticals's Earnings Preview

> NRX Pharmaceuticals (NRXP) is set to release its quarterly earnings report on May 15, 2025, with analysts predicting an earnings per share (EPS) of $-0.40. Investors are hopeful for positive guidance despite a 37.22% decline in share price over the past year, trading at $2.29 as of May 13. The upcoming announcement is crucial as stock prices may be influenced more by future projections than past performance.

NRX Pharmaceuticals NRXP will release its quarterly earnings report on Thursday, 2025-05-15. Here's a brief overview for investors ahead of the announcement.

Analysts anticipate NRX Pharmaceuticals to report an **earnings per share** (EPS) of $-0.40.

Investors in NRX Pharmaceuticals are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.

It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.

Here's a look at NRX Pharmaceuticals's past performance and the resulting price change:

### Performance of NRX Pharmaceuticals Shares

Shares of NRX Pharmaceuticals were trading at $2.29 as of May 13. Over the last 52-week period, shares are down 37.22%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.

**To track all earnings releases for NRX Pharmaceuticals visit their earnings calendar on our site.**

*This article was generated by Benzinga's automated content engine and reviewed by an editor.*

### Related Stocks

- [NRXP.US - NRX Therapeutics](https://longbridge.com/en/quote/NRXP.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 最好的进攻策略是拥有坚实的防守 | 投资者涌向防御性股票  一场安静但强大的轮动正在进行中。消费品类股票相对于非必需品类股票的表现是几十年来最强劲的，苹果的表现像是一个对冲工具，投资者为安全支付了增长倍数。但在今天的市场中，防御性股票已不再便宜。以下是一些图表，稍微揭示了当前 | [Link](https://longbridge.com/en/news/276433851.md) |
| 深入了解 Waymo 最大的无人驾驶出租车车库 | 查看 Waymo 最大的机器人出租车车库内部 | [Link](https://longbridge.com/en/news/276108243.md) |
| 以目标为导向的健身：这位 F45 Training 领导者如何身体力行 | 亚德里安·弗米格（Adrian Furminger），F45 Training 亚太区总经理，分享了他从健康危机到领导一个拥有 1500 家全球工作室的健身品牌的旅程。F45 结合了高强度间歇训练、循环训练和功能性训练，课程时长为 45 分 | [Link](https://longbridge.com/en/news/276434353.md) |
| 美国最危险的工作揭晓 | 在 2024 年，美国记录了 5,070 起致命工作伤害，比 2023 年减少了 4%。卡车司机和建筑工人受到的影响尤为明显，卡车司机的死亡人数达到了 798 人。道路事故减少了 8.5%，而行人事故则上升了 19%。谋杀和自杀导致 733 | [Link](https://longbridge.com/en/news/276462715.md) |
| Ross Gerber 表示，在自动驾驶出租车事故频发的情况下，情况似乎没有好转，并称特斯拉可能需要进行 “硬件调整” | 投资者罗斯·格伯（Ross Gerber）认为，特斯拉的全自动驾驶（FSD）技术由于最近涉及其机器人出租车的事故，需要进行硬件升级。他在社交媒体上表达了担忧，称 FSD 没有改善，并建议特斯拉可能需要考虑引入激光雷达传感器，类似于竞争对手。 | [Link](https://longbridge.com/en/news/276202408.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.